Patrys Limited (AU:PAB) has released an update.
Patrys Limited has announced a shift in its clinical development strategy, moving away from PAT-DX1 due to production challenges and potential safety concerns. The company will concentrate its efforts on PAT-DX3, an antibody with higher yield and stability, which is poised for commercial scale production. Patrys aims to leverage its existing data to explore co-development and licensing partnerships for PAT-DX1, while also investigating the potential of deoxymabs in inflammatory conditions.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
